vTv Therapeutics is a biotechnology business based in the US. vTv Therapeutics shares (VTVT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.24 – a decrease of 9.07% over the previous week. vTv Therapeutics employs 16 staff and has a trailing 12-month revenue of around $1 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $13.24 |
|---|---|
| 52-week range | $7.38 - $30.99 |
| 50-day moving average | $14.60 |
| 200-day moving average | $17.37 |
| Wall St. target price | $2.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-6.83 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.24 from 2024-10-14
| 1 week (2024-10-08) | -9.07% |
|---|---|
| 1 month (2024-09-13) | -7.15% |
| 3 months (2024-07-15) | -44.25% |
| 6 months (2024-04-15) | -47.04% |
| 1 year (2023-10-13) | 2,740.59% |
|---|---|
| 2 years (2022-10-14) | 1,447.81% |
| 3 years (2021-10-15) | 800.68% |
| 5 years (2019-10-15) | 825.87% |
| Revenue TTM | $1 million |
|---|---|
| Gross profit TTM | $-9,933,000 |
| Return on assets TTM | -41.48% |
| Return on equity TTM | -362.13% |
| Profit margin | 0% |
| Book value | $6.77 |
| Market Capitalization | $35.4 million |
TTM: trailing 12 months
We're not expecting vTv Therapeutics to pay a dividend over the next 12 months.
vTv Therapeutics's shares were split on a 1:40 basis on 20 November 2023. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your vTv Therapeutics shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for vTv Therapeutics shares which in turn could have impacted vTv Therapeutics's share price.
Over the last 12 months, vTv Therapeutics's shares have ranged in value from as little as $7.38 up to $30.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while vTv Therapeutics's is 0.63. This would suggest that vTv Therapeutics's shares are less volatile than average (for this exchange).
vTv Therapeutics Inc. , a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.